Skip to content
Head to head

Celldex Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: CLDX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

CLDX +5.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
CLDXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price27.42515.02
Change today-1.93%-1.08%
1-year return+9.4%+22.0%
Market cap$2.15B$130.58B
52-week range22.33 – 45.14412.27 – 568.67
Valuation
P/E (TTM)-6.3933.14
P/E percentile, own 5-yr range99th99th
P/B3.326.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.9015.32
Net profit (TTM)$-306.33M$3.88B
Revenue (TTM)$158.00K$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin100.0%85.5%
Operating margin-211684.8%33.1%
Net margin-195608.9%30.7%
Free cash flow (TTM)$-259.74M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership118.5%96.8%
Insider activity (12mo)44 buy / 6 sell28 buy / 22 sell
Short interest (% of float)12.7%1.9%
Analyst consensus91% buy / 9% hold (11)95% buy / 5% hold (21)
Analyst price target$67 (+145%)$624 (+21%)
StockVane view
StockVane Quant RatingD (53)C (68)
Company
Employees1986,400
Founded19831989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.